Analyst Price Targets — IOVA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 5, 2026 12:53 pm | Andrea Newkirk | Goldman Sachs | $2.00 | $2.44 | TheFly | Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs |
| May 16, 2025 8:43 am | David Dai | UBS | $2.00 | $1.66 | TheFly | Iovance Biotherapeutics downgraded to Neutral from Buy at UBS |
| February 28, 2025 11:49 am | — | Piper Sandler | $6.00 | $4.24 | TheFly | Iovance Biotherapeutics price target lowered to $6 from $7.50 at Piper Sandler |
| January 31, 2025 11:40 am | Joseph Catanzaro | Piper Sandler | $7.50 | $5.85 | TheFly | Iovance Biotherapeutics price target lowered to $7.50 from $10 at Piper Sandler |
| October 24, 2024 3:53 am | David Dai | UBS | $17.00 | $9.82 | StreetInsider | UBS Starts Iovanace Biotherapeutics (IOVA) at Buy |
| August 9, 2024 7:56 am | Benjamin Burnett | Stifel Nicolaus | $11.50 | $3.97 | StreetInsider | Iovanace Biotherapeutics (IOVA) PT Lowered to $23 at Stifel |
| August 9, 2024 6:35 am | Colleen Kusy | Robert W. Baird | $12.00 | $3.97 | StreetInsider | Iovanace Biotherapeutics (IOVA) PT Lowered to $24 at Baird |
| July 29, 2024 2:11 am | Joseph Catanzaro | Piper Sandler | $10.00 | $9.25 | StreetInsider | Piper Sandler Downgrades Iovanace Biotherapeutics (IOVA) to Neutral |
| June 20, 2024 6:20 am | Reni Benjamin | JMP Securities | $11.50 | $4.00 | TheFly | Iovance Biotherapeutics price target lowered to $23 from $25 at JMP Securities |
| May 31, 2024 3:08 pm | Benjamin Burnett | Stifel Nicolaus | $14.00 | $4.44 | StreetInsider | Stifel Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA) |
Latest News for IOVA
SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
A relative unknown, if you don't watch the biotherapeutics industry, Iovance Biotherapeutics ( NASDAQ:IOVA ) surged 43% in the past week after reporting Q4 2025 earnings on February 24, pushing Reddit sentiment to 86 out of 100.
Iovance posts narrower Q4 loss as Amtagvi sales jump 33%. Shares soar on 50% ORR data and plans for registrational sarcoma study.
Iovance Biotherapeutics demonstrates improved Q4 results, with $87M revenue and a 50% gross margin (ex-D&A), but remains high-risk/high-reward. AMTAGVI drives IOVA's prospects, with a modeled $1.6B peak sales and first profit expected in 2028, yet manufacturing and adoption remain challenges. Their cash runway extends into Q3 2027, but dilution risk is material as AMTAGVI is unlikely to generate cash before then;…
Iovance Biotherapeutics (NASDAQ: IOVA) shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarcomas.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IOVA.
U.S. House Trading
No House trades found for IOVA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.